Clinical Trial Search

Primary: The Body Mass Index (BMI in kg/m^2) Using a Bathroom Weighing Scale. — 18.86; 18.17; 19.00; 18.31 Kg/m^2 — p=0.084

Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001

Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30

Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm

Primary: Change in Maximal Voluntary Contraction of the Hip Flexors From Baseline to End of Training and to Post-training — 0.94; 0.98; 1.32; 1.37 kg

Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale

Primary: Sleep and Fatigue — 15.6; 9.0; 10.9; 6.6 units on a scale

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)

Primary: Number of Patients With at Least One Adverse Event — 119 Participants

Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753

Primary: Least Squares Mean Dyskinesia Severity Area Under the Curve (AUC) Score As Assessed By Modified Movement Disorder Society-Unified Dyskinesia Rating Scale (MDS-UDysRS)…

Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio

Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants

Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min

Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change

Primary: Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at Week 12 — 30.4; 33.2 percentage of subjects

Primary: Number of Participants With Clinically Significant Changes in Standard Laboratory Tests — 0 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-1211b — 8; 7; 6; 6 Participants

Primary: Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale — 0; 8 participants — p=0.0007

Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants

Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants

Primary: Peak Unified Dyskinesia Rating Score (UDysRS) — 10.9; 10.8; 13.2 score on a scale — p=0.63

Primary: Efficacy of DHA - Change in Blood ng/dL Levels — 102.18; -13.20 ng/dL - Blood

Primary: Gait Speed (m/s) — 1.14; 1.21; 1.22; 1.20 m/s

Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…

Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…